

ONLINE-ONLY SUPPLEMENTAL MATERIAL

Supplemental Table 1. Clinical responses for men and women receiving NAC

Supplemental Table 2. Multivariable Cox regression for overall survival

Supplemental Table 1. Clinical responses for men and women receiving NAC

Response	Male		Female		P
	N	%	N	%	
Complete clinical response	52	13.5%	15852	23.3%	<0.0001
Partial response	103	26.8%	20284	29.8%	
Response, unknown if complete or partial	87	22.6%	11896	17.5%	
No response	41	10.6%	3381	5.0%	
Unknown ^a	102	26.5%	16652	24.5%	

^aUnknown patients are excluded from the comparative analysis

Supplemental Table 2. Multivariable Cox regression for overall survival

Variable	Hazard ratio	<i>P</i>	95.0% CI for hazard ratio	
			Lower	Upper
Sex (Female vs. Male)	0.888	0.406	0.672	1.174

Adjusted for: Tumor subtype (HR+/HER2-, HR+/HER2+, HR-/HER2+, triple-negative); tumor grade (I, II, III/IV, Unknown); tumor size (T1, T2, T3, T4); nodal status (N0, N1, N2, N3); pCR (Yes, No); age at diagnosis (<50 years, 50-64 years, >64 years); race (White, Black, Other, Unknown); Charlson-Deyo score (0, 1, 2, ≥3); median income (< \$40,227; \$40,227-\$50,353; \$50,354-\$63,332; ≥\$63,333; Unknown).

Abbreviations: CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; pCR, pathologic complete response